altRX vs Henry Meds
altRX has an open FDA warning letter dated June 8, 2026. Henry Meds has none. On compounded semaglutide injection, altRX costs $2,496 less a year at standing rates: $89 a month against $297 a month at Henry Meds. It is one of two products the two sell at comparable terms.
To see where both sit among the other sellers, read our best weight-loss injection providers board.
The record
altRX / Henry Meds
Featured pick (affiliate partner)
altRX
8.8/10
Henry Meds
5.6/10
- RedRock Pharmacy503A
- Health Warehousetype not stated
- Precision Medicinetype not stated
- and 1 more
altRX is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. Henry Meds pays us nothing. The scores are computed the same way for both and are shown as computed (altRX 8.8, Henry Meds 5.6). How we are paid
What the record shows
- 01
altRX has an open FDA warning letter dated June 8, 2026. Henry Meds has none.
- 02
altRX names four pharmacies. Henry Meds names no compounding pharmacy in our record.
- 03
On compounded semaglutide injection, altRX costs $2,496 less a year at standing rates: $89 a month against $297 a month at Henry Meds. It is one of two products the two sell at comparable terms.
- 04
Only altRX lists a price for brand-name semaglutide pen and brand-name tirzepatide pen. Only Henry Meds lists a price for compounded oral semaglutide.
- 05
altRX lists all 50 states. Henry Meds publishes no state list.
Prices and terms, product by product
A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.
altRX
Henry Meds
$89/moLower
$1,068 a year
$297/mo
$3,564 a year
$149/moLower
$1,788 a year
$349/mo
$4,188 a year
$1,149/mo
$13,788 a year
$1,249/mo
$14,988 a year
$249/mo
$2,988 a year
Read off each seller’s own pages. altRX: September 28, 2026. Henry Meds: October 30, 2026. Every plan and dose we hold is on the full review.
The case for each
The case for altRX
8.8/10- $2,496 a year less on compounded semaglutide injection
- $2,400 a year less on compounded tirzepatide injection
- Sells brand-name semaglutide pen and brand-name tirzepatide pen, which Henry Meds does not price
- Names its compounding pharmacy
- Open FDA warning letter, June 8, 2026
The case for Henry Meds
5.6/10- No FDA warning letter on record
- Sells compounded oral semaglutide, which altRX does not price
- Names no compounding pharmacy
- Publishes no state list
Scores
altRX 8.8 · Henry Meds 5.6 out of 10. Six weighted parts.
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
The score is the same formula for every seller. Payment does not enter it. Method
altRX vs Henry Meds: questions
Other sellers we are paid by
Affiliate partners outside this pair. Each has its own record and review, scored the same way.
- Found7.3
From $149/mo
Visit site - Embody9.3
From $79/mo
Visit site - Eden8.7
From $99/mo
Visit site
Sellers closest to these two
- altRX vs Noom
- altRX vs Gala
- altRX vs Hers
- altRX vs Fridays
- Henry Meds vs Direct Meds
- Henry Meds vs Fridays
Matched on molecule, form and price. Every pair we list · The register
Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks